CALIGAN PARTNERS LP enters VERRICA PHARMACEUTICALS INC. with 923.91K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Indirect Derivatives
Filed: 12/30/2025ACC: 0000902664-25-005416
Other
Since Dec 2025
923.91K
Baseline shares
0.00
Direct ownership
0 positions
5.58M
Derivative underlying
3 instruments
1
Security positions
923.91K indirect
Non-Derivative Holdings1
Common Stock, par value $0.0001 per share ("Common Stock")
IndirectShares owned923.91K
Total
923.91K indirect923.91K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock") | 923.91K | Indirect |
| Total | 923.91K | 923.91K indirect |
Derivative Holdings3
Pre-Funded Warrants (right to buy)
IndirectUnderlying security
Common Stock
Underlying shares
4.13M
Shares owned
N/A
Exercise price
0.0001
Expiration
—
Exercise window
—
Series C Warrants (right to buy)
IndirectUnderlying security
Common Stock
Underlying shares
1.03M
Shares owned
N/A
Exercise price
6.315
Expiration
—
Exercise window
—
Series B Warrants (right to buy)
IndirectUnderlying security
Common Stock
Underlying shares
421.35K
Shares owned
N/A
Exercise price
13.35
Expiration
—
Exercise window
—
Total
Underlying
5.58M
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Pre-Funded Warrants (right to buy) Indirect | Common Stock | 0.0001 | — | — | 4.13M | N/A |
| Series C Warrants (right to buy) Indirect | Common Stock | 6.315 | — | — | 1.03M | N/A |
| Series B Warrants (right to buy) Indirect | Common Stock | 13.35 | — | — | 421.35K | N/A |
| Total | 5.58M | 0.00 | ||||